top of page

Ambulero will file an IND for our lead gene therapy product AMB-301 by late 2024.


Ambulero is a pioneer in the use of gene and cell therapy approaches to enhance expression of a key cell adhesion molecule (E-selectin) to treat vascular disease and non-healing wounds. We are pleased to announce our commitment to file an Investigational New Drug (IND) application for our lead product, AMB-301, by late 2024. Once achieved, this significant milestone will bring us closer to testing this  gene therapy drug in the clinic.  

Investment Background and National Recognition:

  • 2023: NIH Approves Second Phase of Funding to Support IND-enabling Work for First-In-Class Ambulero Gene Therapy to Treat Vascular Disease Via The NHLBI Catalzye Program.

  • 2023: Ambulero selected to participate in the Endless Frontier Labs (EFL) small business incubator of the NYU/Stern School of Business, New York.

  • 2022: Biopitch Semi-Finalist at BioFlorida conference.

  • 2022: Ambulero awarded a Cade Prize for its gene therapy approach to treat vascular disease.  The award recognizes innovative technology companies within the Southeastern United States. 

  • 2022: Dr. Velazquez inducted into the American Academy of Medicine for groundbreaking research that forms the basis of Ambulero’s cell and gene therapy platform.

  • 2021: FDA grant of Orphan Drug Designation.

  • 2019: Initial start-up funding, management, and business support provided by Ventac Holding, LLC.

  • 2018: The research work of Dr. Velazquez and Dr. Liu supported by the  Wallace H. Coulter Center for Translational Research at the University of Miami.

  • 2014: Dr. Omaida Velazquez and Zhao-Jun Liu’s research supported for over a decade by grants from the NIH including funding from the prestigious Vascular Interventions/Innovations and Therapeutic Advances (VITA) program, as well as the Catalyze program of NHLBI.


For more information see the following links :

  1. Ventac Partners

  2. NIH VITA Program

  3. NHLBI Catalyze Program 

  4. Wallace H. Coulter Foundation  

  5. Coulter Center, University of Miami

  6. National Academy of Medicine News

  7. Cade Prize

  8. NYU/Stern Endless Frontier Labs

  9. BioFlorida Award

  10. FDA Orphan Drug Designation

bottom of page